Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.
Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer
Revisit the OncLive On Air Episodes From February 2024
Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer
Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
Acalabrutinib Yields Long-Term Efficacy in a Pooled Analysis of Higher-Risk CLL
Risk Factors Could Inform BTK Inhibitor and Venetoclax Sequencing in CLL/SLL
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC